Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13301 - 13325 of 15194 in total
Acifluorfen is a protoporphyrinogen oxidase inhibitor.
Experimental
BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
Investigational
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and
FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]
Investigational
Matched Description: … It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin …
Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
Investigational
Withdrawn
Matched Description: … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported …
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and
Experimental
A non-metabolizable galactose analog that induces expression of the LAC operon.
Experimental
Experimental
Experimental
Displaying drugs 13301 - 13325 of 15194 in total